Abstract Details

Title miRNA as biomarkers of NEDA-3 in multiple sclerosis patients treated with fingolimod, glatiramer acetate and dimethyl-fumarate: Preliminary results

Topic Multiple Sclerosis

Presentation(s) P2 - Poster Session 2 (11:45 AM-12:45 PM)

Poster/Presentation
Number 12-004

Objective

The objective of the present study is to evaluate the potential role of miRNA as biomarkers of NEDA-3 at two years in patients with relapsing remitting multiple sclerosis (RRMS) treated various disease modifying therapies (DMTs) fingolimod, glatiramer acetate (GA) and Dimethyl-fumarate (DMF).

Background

Over the past decade, different microRNA (miRNA) expression patterns have been found to be associated with multiple sclerosis (MS) type and disease progression, being considered potential biomarkers of disease and disability.

Design/Methods We identified 80 RRMS patients, diagnosed by the McDonald criteria grouped by the presence or absence of NEDA-3 at two years under fingolimod, GA or DMF treatment. Serum samples were obtained between 6 and 12 months after treatment start. Patients achieving NEDA-3 at two years were patients whose EDSS remains unchanged, have no relapse nor disease activity in MRI during the two years follow-up period. miRNA expression was performed by RNA extraction followed by RT-PCR using a panel of miRNA expressed in human serum samples.

Results We included a total of 80 patients, with 31 patients on fingolimod treatment, 24 patients on DMF and 25 patients on GA treatment. Of these, 60/80 (75%) were women, mean age was 40 (SD: 10) years, mean EDSS was 1.4 (SD: 1). Univariate analysis assessing the presence of NEDA-3 at two years identified 12 miRNA that were differentially expressed (p<0.05) in fingolimod patients, 37 miRNA in GA patients (p<0.05) and 14 miRNA in DMF patients (p<0.05)

Conclusions Our preliminary results show differences in miRNA expression at early stages after DMT start in patients with MS regarding sustained NEDA-3 at two years. These results suggest that miRNA could be a potential biomarker of treatment response. Further validation and research need to be performed to better understand the role of miRNA as response biomarkers.

Authors/Disclosures
Hrishikesh A. Lokhande (Brigham and Womens Hospital) PRESENTER	Mr. Lokhande has nothing to disclose.
Alicia Gonzalez-Martinez, MD (Hospital Universitario de La Princesa)	Dr. Gonzalez-Martinez has nothing to disclose.
Brian C. Healy	The institution of Mr. Healy has received research support from Analysis Group. The institution of Mr. Healy has received research support from Bristol-Myers Squibb. The institution of Mr. Healy has received research support from Verily Life Sciences. The institution of Mr. Healy has received research support from Novartis. The institution of Mr. Healy has received research support from Merck Serono. The institution of Mr. Healy has received research support from Genzyme.
Anu Paul, PhD (Brigham and Women's Hospital)	Anu Paul has nothing to disclose.
	No disclosure on file
Mariann Polgar-Turcsanyi (Brigham and Women's Hospital)	No disclosure on file
Howard L. Weiner, MD (Brigham and Women'S Hospital)	Dr. Weiner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Weiner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medday Pharmaceuticals. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for vTv Therapeutics. Dr. Weiner has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Tiziana Life Sciences. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for vTv Therapeutics. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medday Pharmaceuticals. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for vTv Therapeutics. Dr. Weiner has stock in vTv Therapeutics. The institution of Dr. Weiner has received research support from National Institute of Health. The institution of Dr. Weiner has received research support from National MS Society. The institution of Dr. Weiner has received research support from Genzyme Corp. The institution of Dr. Weiner has received research support from Genentech, Inc. . The institution of Dr. Weiner has received research support from Verily Life Sciences LLC. The institution of Dr. Weiner has received research support from EMD Serono, Inc..
Tanuja Chitnis, MD, FAAN (Brigham and Women's Hospital)	Dr. Chitnis has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Chitnis has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche-Genentech. Dr. Chitnis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Octave Biosciences. Dr. Chitnis has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. The institution of Dr. Chitnis has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Chitnis has received research support from Novartis. The institution of Dr. Chitnis has received research support from Sanofi. The institution of Dr. Chitnis has received research support from Octave. The institution of Dr. Chitnis has received research support from Genentech-Roche. The institution of Dr. Chitnis has received research support from Tiziana Life Sciences. The institution of Dr. Chitnis has received research support from Bristol-Myers Squibb. The institution of Dr. Chitnis has received research support from Wesley Clover.

��ɫ��

��ɫ��